Slab-Specific Projection-Resolved Optical Coherence Tomography Angiography for Enhancing En Face Polyp Detection in Polypoidal Choroidal Vasculopathy
Investigative Ophthalmology & Visual Science · 2025
DOI: 10.1167/iovs.66.1.9 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2025. Written by Nida Wongchaisuwat and 6 co-authors. Institution: Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. Major MEDLINE topics: Tomography, Optical Coherence, Polyps, Fluorescein Angiography, Algorithms. Cited 4 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NEI NIH HHS, NCATS NIH HHS.
Abstract (original language)
Purpose
A projection-resolved optical coherence tomography angiography (PR-OCTA) algorithm with slab-specific strategy was applied in polypoidal choroidal vasculopathy (PCV) to differentiate between polyp and branching vascular network (BVN) and improve polyp detection by en face OCTA.
Methods
Twenty-nine participants diagnosed with PCV by indocyanine green angiography (ICGA) and 30 participants diagnosed with typical neovascular age-related macular degeneration (nAMD) were enrolled. Polyps were classified into three categories after using the slab-specific PR algorithm. Type 1 polyps were considered in high-elevated pigment epithelial detachment (PED) and displayed in green. Type 2 polyps were considered in low-elevated PED and encoded in yellow, similar to BVN structures. Type 3 polyps were not able to be detected on OCTA. The algorithms were tested in the nAMD group to differentiate PCV and typical nAMD.
Results
With the algorithm, type 1 polyps were readily differentiated from BVN on en face OCTA. Polyp detection rate on en face OCTA only (type 1) was 68%, which was significantly improved from 30% when the algorithm was not used (P = 0.0001). To identify type 2 polyps, a combination of en face and cross-sectional OCTA images was needed and this resulted in a 91% polyp detection rate (types 1 and 2). The absence of luminal structure on OCT at the polyp site, small polyp size, and absence of halo on ICGA appeared to influence the polyp detection rate. When applying the algorithm to the nAMD group, 83% were correctly classified as typical nAMD (absence of type 1 polyps), whereas 17% showed false detection of polyps due to flow signals at the apices of large PEDs.
Conclusions
The slab-specific PR-OCTA with different color coding provides significant improvement in detecting polyp structures on en face OCTA, leading to rapid coronal visualization and diagnosis of PCV without the risk of dye injection.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States.
Funding
- NEI NIH HHS
- NCATS NIH HHS
Cite
APA
Wongchaisuwat, N., Wang, J., Hormel, T. T., Jia, Y., White, E. S., Rodanant, N., & Phasukkijwatana, N. (2025). Slab-Specific Projection-Resolved Optical Coherence Tomography Angiography for Enhancing En Face Polyp Detection in Polypoidal Choroidal Vasculopathy. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.1.9
Vancouver
Wongchaisuwat N, Wang J, Hormel TT, Jia Y, White ES, Rodanant N, et al. Slab-Specific Projection-Resolved Optical Coherence Tomography Angiography for Enhancing En Face Polyp Detection in Polypoidal Choroidal Vasculopathy. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.1.9
BibTeX
@article{Wongchaisuwat2025,
author = {Wongchaisuwat, Nida and Wang, Jie and Hormel, Tristan T and Jia, Yali and White, Elizabeth S and Rodanant, Nuttawut and Phasukkijwatana, Nopasak},
title = {Slab-Specific Projection-Resolved Optical Coherence Tomography Angiography for Enhancing En Face Polyp Detection in Polypoidal Choroidal Vasculopathy},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
doi = {10.1167/iovs.66.1.9}
}
EUVIMED